Physician profile
Heidi U Rula
NPI 1023095742
$1,765.11
in general payments reported to CMS, 2019-2025
32 companies · $542 in 2025
The $542 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $328 · 2021: $59.63 · 2022: $97.43 · 2023: $85.58 · 2024: $446 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,029 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,029.44 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $213.81 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $156.26 | 2019-2025 | Enhertu |
| Davol INC. | $146.46 | 2019 | |
| Eisai INC. | $145.40 | 2022-2025 | |
| Abbvie INC. | $110.03 | 2022-2025 | |
| Lilly USA, LLC | $109.61 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Incyte Corporation | $83.81 | 2020-2025 | Monjuvi, Zynyz, Pemazyre |
| Pharmacyclics LLC, An Abbvie Company | $67.44 | 2021-2023 | Epkinly, Imbruvica |
| Tersera Therapeutics LLC | $59.34 | 2023-2025 | Zoladex |
| Jazz Pharmaceuticals INC. | $59.05 | 2024 | |
| Novartis Pharmaceuticals Corporation | $52.09 | 2024-2025 | |
| Pfizer INC. | $48.51 | 2020-2024 | |
| Stemline Therapeutics INC. | $42.76 | 2024 | Orserdu |
| Janssen Biotech, INC. | $41.75 | 2025 | Balversa, Erleada, Talvey |
| Regeneron Healthcare Solutions, INC. | $39.00 | 2020-2024 | Libtayo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $36.24 | 2023-2024 | Keytruda, Welireg |
| Allergan, INC. | $35.45 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.17 | 2019-2024 | |
| Kite Pharma, INC. | $28.44 | 2024 | Yescarta |
| Iovance Biotherapeutics, INC. | $27.95 | 2025 | Amtagvi |
| Exelixis INC. | $25.05 | 2025 | Cabometyx |
| Genzyme Corporation | $24.47 | 2025 | |
| Gilead Sciences, INC. | $22.16 | 2021 | |
| Rigel Pharmaceuticals, INC. | $21.50 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Amgen INC. | $21.04 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.01 | 2024 | Iclusig |
| Hologic Sales and Service, LLC | $19.20 | 2022 | |
| Celgene Corporation | $16.42 | 2020 | |
| Fennec Pharmaceuticals, INC. | $15.69 | 2025 | Fyarro |
| Dova Pharmaceuticals | $14.11 | 2019 | |
| Blueprint Medicines Corporation | $13.61 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Rula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.